About: Calprotectin in Inflammatory Bowel Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Calprotectin in Inflammatory Bowel Disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Calprotectin in Inflammatory Bowel Disease
Creator	Kashifard, Mehrdad Khaki-Khatibi, Fatemeh Maniati, Mahmood Moein, Soheila Qujeq, Durdi Vaghari-Tabari, Mostafa
Source	Elsevier; Medline; PMC
abstract	Abstract The term IBD is usually used for referring to a group of inflammatory gastro-intestinal diseases (mainly Crohn's disease and ulcerative colitis). Accordingly, IBD arises as a result of inappropriate immune response to intestinal commensal organisms among genetically susceptible individuals. Performing colonoscopy and histopathologic evaluation on an inflamed bowel biopsy specimen are currently considered as gold standards for diagnosis and management of IBD.Correspondingly, these techniques are known to be invasive and costly. In recent decades, fecal calprotectin, as a biomarker, has received much attention for the diagnosis and non-invasive management of IBD.Up to now, many studies have investigated the efficacy of fecal calprotectin in the areas of IBD differentiation from IBS, prediction of endoscopic and histologic activities of IBD and prediction of disease recurrence. Although some of these studies have reported promising results, some others have shown significant limitations. Therefore, in this paper, we reviewed the most interesting ones of these studies after a brief discussion of the laboratory measurement of fecal calprotectin. Moreover, we attempted to provide an answer for the question of whether fecal-calprotectin could be considered as a potential surrogate marker for colonoscopy.
has issue date	2020-08-18(xsd:dateTime)
bibo:doi	10.1016/j.cca.2020.08.025
bibo:pmid	32818491
has license	els-covid
sha1sum (hex)	1a8bbcd02ee5da2110ed5b3829e5f37117057c67
schema:url	https://doi.org/10.1016/j.cca.2020.08.025
resource representing a document's title	Calprotectin in Inflammatory Bowel Disease
has PubMed Central identifier	PMC7431395
has PubMed identifier	32818491
schema:publication	Clin Chim Acta
resource representing a document's body	covid:1a8bbcd02ee5da2110ed5b3829e5f37117057c67#body_text
is schema:about of	named entity 'Performing' named entity 'promising' named entity 'genetically' named entity 'management' named entity 'group' named entity 'fecal' named entity 'calprotectin' named entity 'fecal' named entity 'prediction' named entity 'RECENT' named entity 'STUDIES' named entity 'intestinal' named entity 'calprotectin' named entity 'received' named entity 'diagnosis' named entity 'fecal' named entity 'gold' named entity 'histologic' named entity 'IBD' named entity 'biomarker' named entity 'fecal calprotectin' named entity 'calprotectin' named entity 'disease recurrence' named entity 'IBD' named entity 'genetically susceptible' named entity 'colonoscopy' named entity 'infliximab' named entity 'small bowel' named entity 'Serum' named entity 'calprotectin' named entity 'Infliximab' named entity 'fecal calprotectin' named entity 'trimester of pregnancy' named entity 'fecal calprotectin' named entity 'IBD' named entity 'colonoscopy' named entity 'immunoassays' named entity 'adverse effects' named entity 'differential diagnosis' named entity 'fecal calprotectin' named entity 'inflammatory markers' named entity 'prospective studies' named entity 'IBD' named entity 'fecal calprotectin' named entity 'NSAIDs' named entity 'sensitivity and specificity' named entity 'histologic' named entity 'Neonatal Sepsis' named entity 'fecal calprotectin' named entity 'fecal calprotectin' named entity 'serum levels' named entity 'monoclonal antibodies' named entity 'irritable bowel syndrome' named entity 'relapse' named entity 'sensitivity and specificity' named entity 'histologic' named entity 'calprotectin' named entity 'calprotectin' named entity 'immunoassays' named entity 'fecal calprotectin' named entity 'colonoscopy' named entity 'fecal calprotectin' named entity 'corticosteroid therapy' named entity 'serum levels' named entity 'positive or negative' named entity 'fecal calprotectin' named entity 'fecal calprotectin' named entity 'prognosis' named entity 'long-term' named entity 'pregnancy' named entity 'fecal calprotectin' named entity 'fecal calprotectin' named entity 'histologic' named entity 'CRP' named entity 'calprotectin' named entity 'sensitivity and specificity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software